Showing results (91-100 of 130) with videos related to
Sort By:
Pageof 13
Investigational New Drugs|October 23, 2010
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trialTianhong Li, Scott D Christensen, Paul H Frankel, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 6, 2011
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trialRandeep Sangha, Angela M Davies, Primo N Lara, et al.Journal of Hematology & Oncology|March 2, 2017
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case reportHong Li, Weijie Ma, Ken Y Yoneda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)Joseph A Sparano, Sandra Lee, Michael G Chen, et al.Nature Communications|May 13, 2022
Arabidopsis cryptochrome 2 forms photobodies with TCP22 under blue light and regulates the circadian clockWeiliang Mo, Junchuan Zhang, Li Zhang, et al.Biomaterials|April 14, 2018
Src activation decouples cell division orientation from cell geometry in mammalian cellsXiaoyan Sun, Hongsheng Qi, Xiuzhen Zhang, et al.Journal of Hematology & Oncology|June 12, 2019
High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancerWenwu Xiao, Weijie Ma, Sixi Wei, et al.Journal of Hematology & Oncology|July 28, 2019
Correction to: High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancerWenwu Xiao, Weijie Ma, Sixi Wei, et al.JTO Clinical and Research Reports|December 22, 2022
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLCMatthew S Lara, Matthew A Gubens, Bianca Bacaltos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on ErlotinibPrimo N Lara, Jeff Longmate, Philip C Mack, et al.Pageof 13